Arvinas Inc (ARVN)
26.49
+0.20
(+0.76%)
USD |
NASDAQ |
Jun 12, 16:00
26.38
-0.11
(-0.42%)
Pre-Market: 20:00
Arvinas Enterprise Value: 644.16M for June 12, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 12, 2024 | 644.16M |
| June 11, 2024 | 630.47M |
| June 10, 2024 | 678.38M |
| June 07, 2024 | 657.85M |
| June 06, 2024 | 726.96M |
| June 05, 2024 | 742.70M |
| June 04, 2024 | 824.14M |
| June 03, 2024 | 739.97M |
| May 31, 2024 | 1.099B |
| May 30, 2024 | 1.038B |
| May 29, 2024 | 1.151B |
| May 28, 2024 | 1.244B |
| May 24, 2024 | 1.242B |
| May 23, 2024 | 1.242B |
| May 22, 2024 | 1.292B |
| May 21, 2024 | 1.203B |
| May 20, 2024 | 1.107B |
| May 17, 2024 | 1.068B |
| May 16, 2024 | 1.029B |
| May 15, 2024 | 1.044B |
| May 14, 2024 | 977.42M |
| May 13, 2024 | 991.80M |
| May 10, 2024 | 982.90M |
| May 09, 2024 | 1.018B |
| May 08, 2024 | 1.047B |
| Date | Value |
|---|---|
| May 07, 2024 | 1.181B |
| May 06, 2024 | 1.039B |
| May 03, 2024 | 1.077B |
| May 02, 2024 | 1.047B |
| May 01, 2024 | 1.050B |
| April 30, 2024 | 1.002B |
| April 29, 2024 | 1.010B |
| April 26, 2024 | 1.043B |
| April 25, 2024 | 989.95M |
| April 24, 2024 | 1.054B |
| April 23, 2024 | 1.154B |
| April 22, 2024 | 1.215B |
| April 19, 2024 | 1.203B |
| April 18, 2024 | 1.174B |
| April 17, 2024 | 1.116B |
| April 16, 2024 | 1.116B |
| April 15, 2024 | 1.203B |
| April 12, 2024 | 1.310B |
| April 11, 2024 | 1.377B |
| April 10, 2024 | 1.340B |
| April 09, 2024 | 1.433B |
| April 08, 2024 | 1.403B |
| April 05, 2024 | 1.389B |
| April 04, 2024 | 1.420B |
| April 03, 2024 | 1.467B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-217.05M
Minimum
Oct 27 2023
4.699B
Maximum
Jul 29 2021
1.430B
Average
1.153B
Median
Enterprise Value Benchmarks
| Pfizer Inc | 213.79B |
| Bristol-Myers Squibb Co | 132.03B |
| Alnylam Pharmaceuticals Inc | 18.77B |
| Rhythm Pharmaceuticals Inc | 2.376B |
| IDEAYA Biosciences Inc | 2.284B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -69.40M |
| Revenue (Quarterly) | 25.30M |
| Total Expenses (Quarterly) | 108.60M |
| EPS Diluted (Quarterly) | -0.97 |
| Profit Margin (Quarterly) | -274.3% |
| Earnings Yield | -22.39% |
| Normalized Earnings Yield | -22.39 |